Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

LEVEMIR 100 UNIT/ML VIAL

insulin detemir
$10.3614per ML

Strength

100 [iU]/mL

Manufacturer

Novo Nordisk

NDC

00169368712

Classification

Brand

Dosage Form

INJECTION, SOLUTION

Route

SUBCUTANEOUS

Last Updated

1/22/2025

Active Ingredients

INSULIN DETEMIR

Approval Type

Biologic (BLA)

FDA Application

BLA021536

On Market Since

3/27/2006

Pharmacological Classes

Insulin Analog
Insulin [Chemical/Ingredient]

Price History

1W

0.0%

1M

0.0%

3M

0.0%

6M

0.0%

1Y

0.0%

3Y

-64.9%

5Y

-65.0%

All

-36.4%

Generic Alternatives

Save up to 0%

1 alternative • Same active ingredient

LEVEMIR FLEXPEN 100 UNIT/ML
Brand
00169643210•Novo Nordisk
$10.3587
Save 0%

Related Drugs

Same classification

LANTUS 100 UNIT/ML VIAL
Brand
00088222033•Sanofi-Aventis U.S. LLC
$6.1584
per ML
LANTUS SOLOSTAR 100 UNIT/ML
Brand
00088221905•Sanofi-Aventis U.S. LLC
$6.1661
per ML
HUMALOG 100 UNIT/ML VIAL
Brand
00002751001•Eli Lilly and Company
$6.3604
per ML
NOVOLOG MIX 70-30 VIAL
Brand
00169368512•Novo Nordisk
$6.9325
per ML
FIASP 100 UNIT/ML VIAL
Brand
00169320111•Novo Nordisk
$6.9327
per ML
NOVOLOG 100 UNIT/ML VIAL
Brand
00169750111•Novo Nordisk
$6.9387
per ML
LYUMJEV 100 UNIT/ML VIAL
Brand
00002772801•Eli Lilly and Company
$7.8912
per ML
HUMALOG MIX 75-25 VIAL
Brand
00002751101•Eli Lilly and Company
$8.1530
per ML
APIDRA 100 UNIT/ML VIAL
Brand
00088250033•Sanofi-Aventis U.S. LLC
$8.1717
per ML
NOVOLOG PENFILL 100 UNIT/ML
Brand
00169330312•Novo Nordisk
$8.5732
per ML

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy